With Libtayo's second approval, Regeneron digs deeper into PD-1 dermato-oncology niche
With the sixth checkpoint inhibitor to enter the US market, Regeneron execs have insisted that they can carve out a respectable market share for Libtayo by going to indications that others haven’t. Late Tuesday, the big biotech made another step toward that goal.
The PD-1 drug, also known as cemiplimab, is now indicated for patients with both flavors of advanced basal cell carcinoma — in addition to metastatic cutaneous squamous cell carcinoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.